Adalimumab, which is an anti-human tumor necrosis factor (TNF)-α antibody prescribed for the treatment of rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and other auto-immune diseases [35,36,37], is known to elicit ADA responses in 23% of patients [38]. Here, TNF is linked to rheumatoid arthritis.